Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | RECQL | P46063 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MPO | P05164 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | ALPI | P09923 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | XIAP | P98170 | 1/20 | 0.49 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | TYR | P14679 | 5/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1079739 | 1.00 | MAPT (0.68) | MAPTALDH1A1RECQLKMT2AHIF1A | |
| SCHEMBL16281039 | 0.85 | MAPT (0.68) | MAPTALDH1A1RECQLKMT2AHIF1A | |
| SCHEMBL5281301 | 0.84 | MAPT (0.67) | MAPTALDH1A1RECQLKMT2AHIF1A | |
| SCHEMBL128686 | 0.84 | MAPT (0.67) | MAPTALDH1A1RECQLKMT2AHIF1A | |
| SCHEMBL1060620 | 0.84 | MAPT (0.67) | MAPTALDH1A1RECQLKMT2AHIF1A | |
| SCHEMBL24213670 | 0.84 | MAPT (0.67) | MAPTALDH1A1RECQLKMT2AHIF1A | |
| SCHEMBL20038781 | 0.84 | MAPT (0.67) | MAPTALDH1A1RECQLKMT2AHIF1A | |
| SCHEMBL1059011 | 0.84 | MAPT (0.67) | MAPTALDH1A1RECQLKMT2AHIF1A | |
| SCHEMBL22807019 | 0.84 | MAPT (0.67) | MAPTALDH1A1RECQLKMT2AHIF1A | |
| 1-Methyltryptophan SCHEMBL19992 | 0.84 | MAPT (0.71) | MAPTALDH1A1RECQLKMT2AHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121874142-A | Biosynthesis method of 6-hydroxy-L-tryptophan | 中国科学院海洋研究所 | 2026-04-17 | — | — | CN | disclosed |
| CN-121874142-A | Biosynthesis method of 6-hydroxy-L-tryptophan | 中国科学院海洋研究所 | 2026-04-17 | — | — | CN | disclosed |
| CN-121852342-A | Biosynthesis method of 1-hydroxy-L-tryptophan and derivatives thereof | 中国科学院海洋研究所 | 2026-04-14 | — | — | CN | disclosed |
| CN-121852342-A | Biosynthesis method of 1-hydroxy-L-tryptophan and derivatives thereof | 中国科学院海洋研究所 | 2026-04-14 | — | — | CN | disclosed |
| US-20260062448-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | APELLIS PHARMACEUTICALS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12528836-B2 | Dosing regimens | APELLIS PHARMACEUTICALS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-12458695-B2 | Dosing regimens and related compositions and methods | APELLIS PHARMACEUTICALS, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-3524258-B1 | METHODS OF TREATING CHRONIC DISORDERS WITH COMPLEMENT INHIBITORS | APELLIS PHARMACEUTICALS INC (US) | 2025-10-01 | — | — | EP | disclosed |
| US-20250282823-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | APELLIS PHARMACEUTICALS, INC. | 2025-09-11 | — | — | US | disclosed |
| EP-4585228-A2 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | Apellis Pharmaceuticals, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| WO-2009046198-A2 | SUSTAINED DELIVERY OF COMPSTATIN ANALOGS FROM GELS | POTENTIA PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009015087-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF TRAUMA | POTENTIA PHARMACEUTICALS, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| US-20090005430-A1 | Receptor Blocker and Vasodilator Comprising Indole Derivative as Active Ingredient | NATIONAL UNIVERSITY CORPORATION KANAZAWA UNIVERSITY (JP) | 2009-01-01 | — | — | US | disclosed |
| WO-2008097525-A2 | LOCAL COMPLEMENT INHIBITION FOR TREATMENT OF COMPLEMENT-MEDIATED DISORDERS | POTENTIA PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| EP-1951279-A2 | COMPSTATIN AND ANALOGS THEREOF FOR EYE DISORDERS | Potentia Pharmaceuticals, Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20070238654-A1 | Compstatin and analogs thereof for eye disorders | POTENTIA PHARMACEUTICALS, INC. (US) | 2007-10-11 | — | — | US | disclosed |
| WO-2007044668-A2 | COMPSTATIN AND ANALOGS THEREOF FOR EYE DISORDERS | POTENTIA PHARMACEUTICALS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| WO-2006102760-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2006-10-05 | — | — | WO | disclosed |
| EP-0058111-B1 | 5-ACETYLOXY-L-TRYPTOPHANE AND ITS SALTS, PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTICAL USES | Laboratoires Merck-Clévenot (FR) | 1985-10-23 | — | — | EP | disclosed |
| EP-0058111-A1 | 5-Acetyloxy-L-tryptophane and its salts, process for their preparation and their therapeutical uses | Laboratoires Merck-Clévenot (FR) | 1982-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12458695-B2 | Dosing regimens and related compositions and methods | C1QBP, C3AR1, C9 | MAPT 2753/4885ALDH1A1 4748/4885RECQL 1928/4885 |
| US-20090005430-A1 | Receptor Blocker and Vasodilator Comprising Indole Derivative as Active Ingredient | ADRB2, ADRB1, ADRA2B | MAPT 4780/4885ALDH1A1 2233/4885RECQL 1507/4885 |
| US-20250282823-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | C3AR1, C9, C1QBP | MAPT 3342/4885ALDH1A1 4771/4885RECQL 2739/4885 |
| US-12528836-B2 | Dosing regimens | CFD, CFB, VIP | MAPT 1655/4885ALDH1A1 4785/4885RECQL 4210/4885 |
| US-20260062448-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | MASP2, CLEC4M, C1QBP | MAPT 3096/4885ALDH1A1 4798/4885RECQL 4373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.